Clinical Trials Logo

Clinical Trial Summary

Obtain informed consent from patients with lumbar facet joint syndrome and, after enrollment, randomly assign them to Group A (Joins®) or Group B (Placebo). According to the allocation in each group, participants are instructed to take Joins® 200mg 1 tablet three times a day or placebo 1 tablet three times a day from day 1. Research subjects visit at 4-week intervals a total of 3 times (4 weeks, 8 weeks, 12 weeks) to collect various measurement variables. Both the test and control groups are observed during the period of taking the investigational medication without any changes or additional facet joint-related procedures (medial branch block, facet joint block). Acetaminophen is allowed as a rescue medication.


Clinical Trial Description

First Visit (-4 weeks to 0 weeks, Screening Visit) Check the most severe and average 11-point NRS pain scores in the last 24 hours, as well as the current 11-point NRS pain score. (To be eligible for the study, the average 11-point NRS pain score in the last 24 hours should be 4 or higher.) Conduct demographic survey, confirm concurrent medications and treatments, review medical and surgical history, and perform a physical examination. Measure vital signs. Conduct laboratory tests, and for fertile women, perform a pregnancy test. Perform lumbar X-ray examination. Perform lumbar MRI examination. (This examination can be arranged in advance at an external hospital for the purpose of this study.) Second Visit (0 weeks, Enrollment and Randomization Visit) After confirming the laboratory tests and lumbar X-ray conducted during the last visit, proceed with randomization only if deemed eligible for the study. Measure vital signs. Check the most severe and average 11-point NRS pain scores in the last 24 hours, as well as the current 11-point NRS pain score. Self-assess the questionnaires collected during this visit. Oswestry Disability Index (ODI), PainDETECT, GAD-7, EQ-5D Prescribe the test drug and placebo. Subjects will administer the test drug as follows from the day after the visit: Placebo Group: Administer placebo orally three times a day, one tablet per dose, for 12 weeks. Test Group: Administer Joins® 200 mg orally three times a day, one tablet per dose, for 12 weeks. Confirm concurrent medications and treatments, and check for adverse reactions. Third and Fourth Visits (4 weeks/8 weeks, Treatment Visits) Measure vital signs. Check the most severe and average 11-point NRS pain scores in the last 24 hours, as well as the current 11-point NRS pain score. Self-assess the questionnaires collected during this visit. Oswestry Disability Index (ODI) Subjects return the remaining medication after administration. Confirm compliance and prescribe new test drugs. Confirm concurrent medications and treatments, and check for adverse reactions. Fifth Visit (12 weeks, End of Treatment Visit) Measure vital signs. Check the most severe and average 11-point NRS pain scores in the last 24 hours, as well as the current 11-point NRS pain score. Self-assess the questionnaires collected during this visit. Oswestry Disability Index (ODI), PainDETECT, GAD-7, EQ-5D, PGIC, Satisfaction with Investigational Medication Subjects return the remaining medication after administration. Confirm compliance. Confirm concurrent medications and treatments, and check for adverse reactions. Conduct laboratory tests, and for fertile women, perform a pregnancy test. Sixth Visit (13 weeks, Post-Treatment Follow-up Visit) Measure vital signs. Check for adverse reactions. Conduct laboratory tests, and for fertile women, perform a pregnancy test. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06204952
Study type Interventional
Source Seoul National University
Contact Jee Youn Moon, MD, PhD
Phone 821052992036
Email jymoon0901@gmail.com
Status Not yet recruiting
Phase N/A
Start date June 22, 2024
Completion date April 20, 2026

See also
  Status Clinical Trial Phase
Completed NCT02580383 - Multifidus Muscle Twitch on the Prognosis of Lumbar Medial Branch RF N/A
Recruiting NCT05436873 - MR-HIFU for Non-invasive Thermal Therapy of Facet-Joint Syndrome: N/A
Active, not recruiting NCT04786145 - Cryoneurolysis Outcome on Pain Experience (COPE) in Patients With Low-back Pain N/A
Recruiting NCT03168802 - MRgFUS and RFA for Treatment of Facet-joint Osteoarthritis Low Back Pain N/A
Not yet recruiting NCT04816747 - Intradiscal and Intra-articular Injection of Autologous Platelet-Rich-Plasma (PRP) in Patients With Lumbar Degenerative Disc Disease and Facet Joint Syndrome Phase 3